BriaVax Breast Cancer Vaccine Development Going According to Plan, Company Says

BriaVax Breast Cancer Vaccine Development Going According to Plan, Company Says
BriaCell Therapeutics’ Phase 1/2a study of the breast cancer vaccine BriaVax is proceeding according to plan, the company recently announced. Six patients with advanced breast cancer have received the therapeutic vaccine, which intends to trigger an immune response against the cancer. The study (NCT03066947), in which researchers treated and evaluated the first three patients in a sequential manner, so far has not flagged potential safety issues. The Phase 2a part of the study started when the initial three patients were evaluated, and the company expects to share data on the first 10 patients in early 2018. “Recruitment continues to proceed as projected, despite the challenges presented in recruiting late-stage cancer patients,” the company wrote in a press release. BriaVax is made up of injections of cells that have been genetically modified to release GM-CSF — an immune system activator. An earlier small Phase 1 study showed that the treatment triggered rapid and nearly complete eradication of metastatic breast cancer in the breast, lung, soft tissue, and brain. Patients receiving the cell vaccine are pre-treated with the immunosuppressant cyclophosphamide and get Intron A (interferon alpha-2b) after the vaccine. In addition to testing BriaVax in patients, the company works on developing a so-called companion diagnostic, called BriaDx, to be used together with the vaccine. The idea is that BriaDx would identify patients most likely
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.